|Previous Section||Index||Home Page|
Ms Blears: Voluntary euthanasiathe intentional taking of life at the patient's requestis unlawful in the United Kingdom. Anyone alleged to have undertaken it would be open to a charge of murder or manslaughter. Similarly, medical treatment that is either omitted or given to a patient with the specific intention by the health care professional of hastening or inducing death is an illegal act.
(3) what his Department is doing to promote earlier detection of diabetes; 
(4) what his Department's estimate is of the annual cost of care for a diabetic in financial year 200102; 
(5) what his Department's budget committed to the treatment of diabetes is in 200102; and what it is projected to be for 200203. 
Jacqui Smith: There are an estimated 1.3 million people with diagnosed diabetes in England. Incidence is difficult to predict in diabetes, but it has been estimated that this figure will increase by 3 per cent. each year.
10 Apr 2002 : Column 437W
Information is not collected on the cost of treating individuals with diabetes. Around 5 per cent. of total NHS resources, and up to 10 per cent. of hospital in-patient resources are used for the care of people with diabetes.
The Diabetes National Service Framework: "Standards", published in December 2001, sets 12 standards in nine areas, including the prevention and detection of diabetes. We have asked the National Screening Committee to assess the benefits and drawbacks of screening for Type 2 diabetes. The Committee has decided that further research, which may require some complex studies, is needed to inform its advice. It will report to the Department of Health in 2005.
(3) what guidance has been issued to hospital trusts looking to acquire MASH type mobile operating theatres; 
(4) which hospital trusts are negotiating to acquire MASH type mobile operating theatres. 
Mr. Hutton: The Department does not collect data on how many NHS Trusts are negotiating to acquire mobile operating theatres, or on how many trusts already have them in place. The purchase of mobile operating theatres is a matter for individual NHS trusts to make, in partnership with their commissioners.
Costs for the provision of mobile operating theatres vary according to the type of facility, the costs of securing plumbing and power, and the length of time the facility is likely to be in operation, as well as a range of site-specific conditions. However, the approximate costs are £3,600 a day or £12,000 per week for a "low loader" facility (which can be moved around from day to day) and for Modular kits, which provide a fixed-temporary service, the cost is £1,200 a day or £750,000 as an outright purchase.
Guidance on ventilation in health care premises and operating departments have been issued by NHS Estates. In 1991, NHS Estates issued "Health Building Note 26 on Operating Departments" which covers the planning and design, including space requirements, maintenance, cleaning, energy consumption, engineering and staffing requirements. While the guidance does not refer directly to mobile operating theatres, the standards set out in the guidance applies to all types of operating theatre. Health Technical Memorandum 2025 was issued in 1993 and sets out how the NHS can ensure facilities control and reduce hazards to patients and staff from airborne contaminants, dust and harmful micro-organisms.
10 Apr 2002 : Column 438W
Jacqui Smith: We commissioned the National Institute for Clinical Excellence (NICE) to produce guidance on inhalers for children under five with chronic asthma. Guidance on that topic was issued in September 2000. Further guidance was commissioned from NICE on the clinical and cost effectiveness of inhalers in older children. This appraisal will be available on the NICE website (www.nice.nhs.uk) from 11 April.
Yvette Cooper: Standards of a maximum wait of one month from diagnosis to first treatment for breast cancer and one month from urgent GP referral to treatment for children's and testicular cancers and acute leukaemia came into effect at the end of December 2001. Central monitoring of these standards began on 1 January 2002 and data will be published on a quarterly basis. Data collection on waiting times to treatment for other tumour types will be introduced as we roll out the Cancer Plan waiting times targets.
Jacqui Smith: Quarterly information on re-admissions is only collected for those aged 75 and over. We currently anticipate that the Quarter 4 (January-March) 200102 information will be available late in May.
Ms Blears: Security and safety of staff, patients and property in the national health service is of great importance to the Government. It is for health authorities in partnership with primary care trusts and other local stakeholders to determine how best to use their funds to meet national and local priorities for improving health, tackling health inequalities and modernising services.
Security is provided in trusts by 'in-house' staff or by private security organisations. The method of provision and level of staffing is a matter for individual trusts dependent on the size of the hospital, the locality, staffing levels and the general configuration of the building.
10 Apr 2002 : Column 439W
Guidance on effective management of security in accident and emergency departments was issued by the NHS Executive in 1997 and was an important aspect of the Government strategy when funding the upgrading of A and E departments.
Tim Loughton: To ask the Secretary of State for Health what the policy of his Department is on sending national health service patients for treatment in South Africa; and which health authorities have approached his Department about sending NHS patients for treatment in South Africa. 
Mr. Hutton: Our policy on commissioning health care outside the European Economic Area remains that such commissioning should only take place where exceptional circumstances apply. No health authorities have approached the Department about sending NHS patients for treatment in South Africa.
Ms Blears: In 1999 we decided to constrain the spend on drug treatments for impotence broadly within the range £12-£14 million a year, the approximate amount that was being spent on these treatments before the first oral treatment became available. The medical conditions conferring eligibility for NHS prescriptions from GPs were those believed to be commonly associated with impotence that we estimated could be met within the spending range (although, in fact, latest figures indicate that annual expenditure on drug treatments for impotence is £25 million). This does not mean that patients suffering from impotence arising from other causes have no access to drug treatment on the NHS. NHS treatment for such patients is available from specialist services where impotence is causing severe distress.
|Next Section||Index||Home Page|